MA26859A1 - Forme posologique de medicament commandée par un hydrogel. - Google Patents

Forme posologique de medicament commandée par un hydrogel.

Info

Publication number
MA26859A1
MA26859A1 MA26695A MA26695A MA26859A1 MA 26859 A1 MA26859 A1 MA 26859A1 MA 26695 A MA26695 A MA 26695A MA 26695 A MA26695 A MA 26695A MA 26859 A1 MA26859 A1 MA 26859A1
Authority
MA
Morocco
Prior art keywords
drug
dosage form
water
hydrogel
nucleus
Prior art date
Application number
MA26695A
Other languages
English (en)
Inventor
Elizabeth Appel Leah
Arthur Beyerinck Ronald
Brian Chidlaw Mark
John Curatolo William
Thomas Friesen Dwayne
Lincoln Smith Kelly
Govind Thombre Avinash
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26859A1 publication Critical patent/MA26859A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DEPOSANT Sociétés dites : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 23/12/1999 60/171,968 Voir en annexe le titre de l'invention et le texte de l'abrégé "Forme posologique de médicament commandée par un hydrogel" Une forme posologique à libération contrôlée comprend un noyau enrobé, le noyau comprenant une composition contenant un médicament et une composition pouvant gonfler dans l'eau, chacune occupant des régions distinctes dans le noyau. La composition contenant un médicament comprend un médicament à faible solubilité et un agent d'entraînement de médicament. L'enrobage autour du noyau est perméable à l'eau et insoluble dans l'eau et comporte au moins un orifice de libération. Diverses formulations ayant des profils spécifiques de libération de médicament sont décrites.
MA26695A 1999-12-23 2002-06-18 Forme posologique de medicament commandée par un hydrogel. MA26859A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17196899P 1999-12-23 1999-12-23

Publications (1)

Publication Number Publication Date
MA26859A1 true MA26859A1 (fr) 2004-12-20

Family

ID=22625827

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26695A MA26859A1 (fr) 1999-12-23 2002-06-18 Forme posologique de medicament commandée par un hydrogel.

Country Status (42)

Country Link
US (3) US20020015731A1 (fr)
EP (2) EP1967185A1 (fr)
JP (1) JP4100910B2 (fr)
KR (1) KR100523127B1 (fr)
CN (1) CN1402632A (fr)
AP (1) AP2002002553A0 (fr)
AR (1) AR027091A1 (fr)
AT (1) ATE392890T1 (fr)
AU (1) AU783685B2 (fr)
BG (1) BG106865A (fr)
BR (1) BR0016708A (fr)
CA (1) CA2395333C (fr)
CR (1) CR6656A (fr)
CZ (1) CZ20022046A3 (fr)
DE (1) DE60038698T2 (fr)
DK (1) DK1242055T3 (fr)
DZ (1) DZ3228A1 (fr)
EA (1) EA004370B1 (fr)
EE (1) EE200200361A (fr)
ES (1) ES2302705T3 (fr)
GE (1) GEP20043334B (fr)
GT (1) GT200000222A (fr)
HU (1) HUP0301242A3 (fr)
IL (1) IL149224A0 (fr)
IS (1) IS6340A (fr)
MA (1) MA26859A1 (fr)
MX (1) MXPA02006328A (fr)
NO (1) NO20022970D0 (fr)
NZ (1) NZ518281A (fr)
OA (1) OA12128A (fr)
PA (1) PA8509001A1 (fr)
PE (1) PE20010985A1 (fr)
PL (1) PL357535A1 (fr)
PT (1) PT1242055E (fr)
SI (1) SI1242055T1 (fr)
SK (1) SK8572002A3 (fr)
SV (1) SV2002000250A (fr)
TN (1) TNSN00253A1 (fr)
TR (1) TR200201646T2 (fr)
WO (1) WO2001047500A1 (fr)
YU (1) YU35302A (fr)
ZA (1) ZA200204960B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053791A1 (en) 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7678387B2 (en) * 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US20070059367A1 (en) * 2000-06-06 2007-03-15 Cherukuri S R Drug Delivery System and Associated Methods
US20100196466A1 (en) * 2000-06-06 2010-08-05 Capricorn Pharma Inc. Drug delivery system
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CA2450748A1 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques contenant des ensembles polymere et medicament
JP2005515966A (ja) 2001-07-06 2005-06-02 エンドー ファーマシューティカルズ， インコーポレイティド 鎮痛薬としての使用のための６−ヒドロキシ−オキシモルホンの経口投与
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
CN1625397A (zh) * 2002-02-01 2005-06-08 辉瑞产品公司 胆固醇酯转移蛋白抑制剂的控制释放药物剂型
WO2003096968A2 (fr) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Systeme de delivrance orale osmotique controlee de medicament
US20040076668A1 (en) * 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
WO2004050068A1 (fr) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Compositions pharmaceutiques comprenant un compose medicamenteux respectivement basique, tensioactif et base respectivement acide hydrosoluble et tolerable physiologiquement
EP1596837A2 (fr) * 2003-02-07 2005-11-23 Omega Farma Ehf Formules de venlafaxine a liberation prolongee
WO2004098572A1 (fr) * 2003-05-06 2004-11-18 Ranbaxy Laboratories Limited Liberation biphasique de glipizide contenu dans une forme pharmaceutique osmotique monocompartiment
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
US8715724B2 (en) * 2004-10-29 2014-05-06 Mayne Pharma International Pty Ltd Tabletting process
WO2006072878A1 (fr) * 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Formes posologiques orales de sertraline possedant une taille de particule controlee, et leurs procedes de preparation
GB0504547D0 (en) * 2005-03-04 2005-04-13 Delsol Products Ltd Personal lubricant
US20080213381A1 (en) * 2005-03-14 2008-09-04 Pharmaceutical Industries Limited Oral Drug Delivery System
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080242642A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US7541347B2 (en) 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
WO2007057762A2 (fr) * 2005-11-16 2007-05-24 Pfizer Limited Forme posologique a liberation controlee
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
CN101439026B (zh) * 2007-11-23 2011-04-06 北京红林制药有限公司 含有多沙唑嗪或其盐的控释制剂及其制备方法
CN102026628A (zh) * 2008-02-15 2011-04-20 太阳医药高级研发有限公司 具有降低崩裂效果的口服控释片剂
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
KR101284368B1 (ko) 2010-07-09 2013-07-15 서울대학교산학협력단 나노섬유시트 기재의 경구용 약물의 제어 전달을 위한 시스템
WO2012103411A2 (fr) * 2011-01-28 2012-08-02 Zx Pharma, Llc Composition de mélatonine à libération contrôlée et procédés associés
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
HUE045625T2 (hu) * 2013-01-30 2019-12-30 Daewoong Co Ltd Gyógyászati kompozíciók sebek védelmére, vérpangás szolgáltatására, vagy összetapadás megakadályozására a gyomor- és bél traktusban
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
US9895308B2 (en) 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
US20170182070A1 (en) 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
WO2017035408A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés pour le traitement de troubles immunitaires et inflammatoires
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
SG11201811491YA (en) 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
EP3866773B1 (fr) 2018-10-16 2024-08-28 Georgia State University Research Foundation, Inc. Promédicaments de monoxyde de carbone pour le traitement de troubles médicaux
JP7812785B2 (ja) 2019-09-18 2026-02-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｙｋ２阻害薬の剤形
WO2021127452A1 (fr) 2019-12-19 2021-06-24 Georgia State University Research Foundation, Inc. Composés pour le traitement d'infections bactériennes et la potentialisation d'antibiotiques
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
MX2023000479A (es) * 2020-07-10 2023-02-13 Adare Pharmaceuticals Inc Composiciones farmaceuticas orales hinchables.
IL301389A (en) 2020-09-18 2023-05-01 Bristol Myers Squibb Co Dosage forms for tyk2 inhibitors comprising swellable cores
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物
WO2023063381A1 (fr) * 2021-10-14 2023-04-20 静岡県公立大学法人 Formulation médicamenteuse en poudre
US20250242031A1 (en) * 2022-02-14 2025-07-31 Purdue Research Foundation Polymer salts for improved drug delivery from amorphous solid dispersions

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
IT1165797B (it) * 1982-10-18 1987-04-29 Consiglio Nazionale Ricerche Procedimento di preparazione di alchilangelicine esenti da psoraleni ed alchilangolicine ottenute col procedimento
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4865598A (en) * 1985-08-16 1989-09-12 Alza Corporation Dispensing system for administering beneficial agent
EP0277092B1 (fr) * 1987-01-14 1992-01-29 Ciba-Geigy Ag Système thérapeutique pour médicaments peu solubles
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5186942A (en) * 1989-01-30 1993-02-16 Alza Corporation Nicardipine therapy
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US5019396A (en) * 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5200197A (en) * 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
US5151450A (en) * 1990-02-22 1992-09-29 Tokyo Tanabe Company, Limited Antiulcer substance
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
EP0550641B1 (fr) * 1990-09-28 1994-05-25 Pfizer Inc. Dispositif de distribution contenant un milieu hydrophobe
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
EP0607321A1 (fr) * 1991-10-10 1994-07-27 Alza Corporation Dispositifs de perfusion osmotique de medicaments utilisant des materiaux de paroi hydrophobes
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
US5185158A (en) * 1992-02-27 1993-02-09 Alza Corporation Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same
SK281042B6 (sk) * 1992-09-18 2000-11-07 Yamanouchi Pharmaceutical Co., Ltd Prípravok hydrogélového typu s ustáleným uvoľňovaním
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
GB9326267D0 (en) * 1993-12-23 1994-02-23 Scherer Corp R P Expulsion of material
US5458888A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
HUT77530A (hu) * 1994-05-06 1998-05-28 Pfizer Inc. Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5582591A (en) * 1994-09-02 1996-12-10 Delab Delivery of solid drug compositions
US5718700A (en) * 1994-09-20 1998-02-17 Alza Corporation Exit means in dosage form
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5607696A (en) * 1995-02-10 1997-03-04 Alza Corporation Osmotic membrane and delivery device
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5817335A (en) * 1995-05-26 1998-10-06 Alza Corporation Osmotic device with high drug loading and delayed activation of drug delivery
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
FR2744733B1 (fr) * 1996-02-08 1998-04-24 Ascometal Sa Acier pour la fabrication de piece forgee et procede de fabrication d'une piece forgee
IT1290764B1 (it) * 1996-05-03 1998-12-10 Vevy Europ S P A Pentapeptide per la preparazione di composizioni dermo- farmaceutiche e cosmetiche per il trattamento di lesioni od affezioni cutanee
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6271278B1 (en) * 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
CA2261787C (fr) * 1997-05-30 2006-11-14 Laboratorios Phoenix U.S.A., Inc. Dispositif a osmose multicouches
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US6245200B1 (en) 1999-12-10 2001-06-12 Sandia Corporation Photo-oxidation method using MoS2 nanocluster materials
JP2003518487A (ja) * 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク ヒドロゲル駆動型積層薬物製剤
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form

Also Published As

Publication number Publication date
NZ518281A (en) 2005-01-28
CN1402632A (zh) 2003-03-12
NO20022970L (no) 2002-06-20
TNSN00253A1 (fr) 2002-05-30
AU783685B2 (en) 2005-11-24
CR6656A (es) 2004-04-29
EP1242055B1 (fr) 2008-04-23
YU35302A (sh) 2005-03-15
DZ3228A1 (fr) 2001-07-05
HUP0301242A3 (en) 2006-07-28
PL357535A1 (en) 2004-07-26
WO2001047500A1 (fr) 2001-07-05
BG106865A (bg) 2003-03-31
EP1242055A1 (fr) 2002-09-25
GT200000222A (es) 2002-06-14
ES2302705T3 (es) 2008-08-01
DE60038698T2 (de) 2009-05-07
PA8509001A1 (es) 2002-02-21
CA2395333C (fr) 2009-01-13
US9028870B2 (en) 2015-05-12
SV2002000250A (es) 2002-02-05
EA004370B1 (ru) 2004-04-29
CA2395333A1 (fr) 2001-07-05
DE60038698D1 (de) 2008-06-05
GEP20043334B (en) 2004-03-10
AR027091A1 (es) 2003-03-12
ATE392890T1 (de) 2008-05-15
TR200201646T2 (tr) 2002-11-21
ZA200204960B (en) 2003-10-02
IS6340A (is) 2002-04-12
IL149224A0 (en) 2002-11-10
DK1242055T3 (da) 2008-07-21
KR20020070330A (ko) 2002-09-05
PE20010985A1 (es) 2001-09-28
NO20022970D0 (no) 2002-06-20
KR100523127B1 (ko) 2005-10-20
CZ20022046A3 (cs) 2002-11-13
EA200200595A1 (ru) 2002-12-26
MXPA02006328A (es) 2002-12-13
OA12128A (en) 2006-05-05
PT1242055E (pt) 2008-07-02
US20020015731A1 (en) 2002-02-07
JP4100910B2 (ja) 2008-06-11
US20110182947A1 (en) 2011-07-28
BR0016708A (pt) 2002-10-08
US20070087057A1 (en) 2007-04-19
SI1242055T1 (sl) 2008-08-31
AU2018901A (en) 2001-07-09
EE200200361A (et) 2003-10-15
JP2003518489A (ja) 2003-06-10
AP2002002553A0 (en) 2002-06-30
HUP0301242A2 (hu) 2004-05-28
EP1967185A1 (fr) 2008-09-10
SK8572002A3 (en) 2002-12-03

Similar Documents

Publication Publication Date Title
MA26859A1 (fr) Forme posologique de medicament commandée par un hydrogel.
KR910009243A (ko) 치근막 질환 치료용 서방성 조성물
TNSN01123A1 (fr) Formes posologiques nouvelles a liberation controlee
BR0014159A (pt) Combinação farmacêutica de etinilestradiol e drospirenona para uso como um anticoncepcional
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
IE970588A1 (en) Controlled release pharmaceutical compositions containing tiagabine
FR2752732B1 (fr) Forme galenique a liberation prolongee de milnacipran
EP1992336A3 (fr) Forme galénique pour la délivrance colique de principes actifs
HUP0003323A2 (hu) Vorikonazolt tartalmazó gyógyászati készítmények
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
CA2371940A1 (fr) Amidon pregelatinise dans une formulation a liberation regulee
EP0382066A3 (fr) Utilisation de l'acide dihydroliponique comme agent analgésique, antiphlogistique et/ou cytoprotecteur
BR9901782A (pt) Forma para dosagem de nefazodona.
ES2125324T3 (es) Film para suministro local de un farmaco para un tratamiento periodontal.
DE69922017D1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
DK1187611T3 (da) Oftalmiske histaminholdige sammensætninger og anvendelse deraf
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
SG145717A1 (en) Composition for releasing a weak base for an extended period of time
CA2382426A1 (fr) Melange pharmaceutique d'ethinylestradiol et de drospirenone utilise en tant que contraceptif
EP1450739A1 (fr) Gel nasal hydratant et applicateur
DE69634080D1 (de) Mittel zur verhinderung der truebung der vorderen linsenkapsel
GEP20043377B (en) Pharmaceutical Complex
ATE415964T1 (de) Abführzusammensetzung,welche l-arginine enthält